Evidence map›Paper›PMID 34117914›Full record

ArticleWorld journal of urology2021

Impact of sex on response to BCG in non-muscle invasive bladder cancer patients: a contemporary review from a tertiary care center.

Kelly K Bree, Patrick J Hensley, Nathan Brooks, Justin Matulay, Graciela M Nogueras-Gonzalez, Neema Navai, Colin P Dinney, Ashish M Kamat

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Kelly K BreeDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Patrick J HensleyDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nathan BrooksDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Justin MatulayDepartment of Urology, Atrium Health Levine Cancer Institute, Charlotte, NC, USA.
Graciela M Nogueras-GonzalezDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Neema NavaiDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Colin P DinneyDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ashish M KamatDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. akamat@mdanderson.org.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Targeting Ral GTPases in Bladder CancerP50CA091846 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DINNEY, COLIN P.N., MCCONKEY, DAVID J. · 2001 to 2018
$37.4M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA091846NIH/NCI UTMD Anderson SPORE in Genitourinary Cancer (Bladder) P50CA091846
6 · The paper itself

Abstract

purposeFemale sex has been implicated with higher stage at diagnosis and as a negative prognostic factor amongst patients with non-muscle invasive bladder cancer (NMIBC). Whether this holds true with contemporary management paradigms is unknown. We analyzed a cohort of patients treated with adequate bacillus Calmette-Guerin (BCG) for NMIBC in an effort to identify sex-specific influence on BCG response.

methodsAn IRB-approved review of patients with NMIBC treated at our institution with at least 'adequate BCG', as defined by the US FDA and EAU, from 2000 to 2018 was performed. Patients were then stratified by sex and response to BCG. Non-parametric tests were used to summarize the data overall and by groups. The Kaplan-Meier product limit method was used to calculate median survival endpoints.

resultsOf the 541 patients treated with adequate BCG, 111 (20.5%) were female and 430 (79.5%) were male. Female patients were younger (median 66 vs. 69, p = 0.071), had a lower BMI (median 27.3 vs. 28.8, p = 0.010) and were more likely to have no smoking history (49.5% vs. 27.0%, p < 0.001). Tumor characteristics with respect to stage, size, multifocality, presence of carcinoma in situ, and presence of variant histology were similar between sexes. While rates of recurrence were higher in females than in males this, was not statistically significant (44.1% vs. 34.7%, p = 0.064) and Kaplan-Meier estimates of recurrence-free, progression-free and overall survival demonstrated no significant difference between sexes (p = 0.409, p = 0.253, p = 0.171, respectively).

conclusionIn a contemporary cohort of patients with NMIBC treated with adequate BCG, female sex was not associated with adverse oncologic outcomes.

Indexed as

Adjuvants, ImmunologicAgedBCG VaccineFemaleHumansMaleMiddle AgedNeoplasm InvasivenessRetrospective StudiesSex FactorsTertiary Care CentersTreatment OutcomeUrinary Bladder NeoplasmsAdjuvants, ImmunologicBCG VaccineBCGBladder cancerGenderNon-muscle invasive bladder cancer

Identifiers

PMID34117914
PMCPMC11951177

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.